Celldex Therapeutics, Inc. (CLDX)
CLDX Stock Price Chart
Explore Celldex Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CLDX price movements and trends.
CLDX Company Profile
Discover essential business fundamentals and corporate details for Celldex Therapeutics, Inc. (CLDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 May 1986
Employees
186.00
Website
https://www.celldex.comCEO
Anthony S. Marucci
Description
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
CLDX Financial Timeline
Browse a chronological timeline of Celldex Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.04, while revenue estimate is $735.75k.
Earnings released on 7 May 2026
EPS came in at -$1.18 falling short of the estimated -$1.15 by -2.86%, while revenue for the quarter reached $15.00k , missing expectations by -98.11%.
Earnings released on 25 Feb 2026
EPS came in at -$1.22 falling short of the estimated -$1.00 by -22.00%, while revenue for the quarter reached $100.00k , missing expectations by -92.40%.
Earnings released on 10 Nov 2025
EPS came in at -$1.01 falling short of the estimated -$0.88 by -14.77%.
Earnings released on 7 Aug 2025
EPS came in at -$0.85 surpassing the estimated -$0.86 by +1.16%, while revenue for the quarter reached $730.00k , missing expectations by -29.09%.
Earnings released on 8 May 2025
EPS came in at -$0.81 falling short of the estimated -$0.75 by -8.00%, while revenue for the quarter reached $695.00k , missing expectations by -30.33%.
Earnings released on 27 Feb 2025
EPS came in at -$0.71 surpassing the estimated -$0.73 by +2.74%, while revenue for the quarter reached $1.18m , beating expectations by +14.71%.
Earnings released on 6 Nov 2024
EPS came in at -$0.64 surpassing the estimated -$0.69 by +7.25%, while revenue for the quarter reached $3.19m , beating expectations by +281.90%.
Earnings released on 8 Aug 2024
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $2.50m , beating expectations by +192.41%.
Earnings released on 6 May 2024
EPS came in at -$0.56 surpassing the estimated -$0.67 by +16.42%, while revenue for the quarter reached $200.00k , missing expectations by -75.28%.
Earnings released on 26 Feb 2024
EPS came in at -$0.83 falling short of the estimated -$0.76 by -9.21%, while revenue for the quarter reached $4.13m , beating expectations by +186.66%.
Earnings released on 2 Nov 2023
EPS came in at -$0.81 falling short of the estimated -$0.67 by -20.90%, while revenue for the quarter reached $1.52m , beating expectations by +160.06%.
Earnings released on 8 Aug 2023
EPS came in at -$0.65 matching the estimated -$0.65, while revenue for the quarter reached $268.00k , missing expectations by -49.24%.
Earnings released on 4 May 2023
EPS came in at -$0.62 surpassing the estimated -$0.63 by +1.59%, while revenue for the quarter reached $967.00k , beating expectations by +135.85%.
Earnings released on 28 Feb 2023
EPS came in at -$0.56 surpassing the estimated -$0.59 by +5.08%, while revenue for the quarter reached $1.61m , beating expectations by +510.98%.
Earnings released on 9 Nov 2022
EPS came in at -$0.57 matching the estimated -$0.57, while revenue for the quarter reached $407.00k , beating expectations by +13.06%.
Earnings released on 8 Aug 2022
EPS came in at -$0.77 falling short of the estimated -$0.46 by -67.39%, while revenue for the quarter reached $163.00k , missing expectations by -59.25%.
Earnings released on 5 May 2022
EPS came in at -$0.49 falling short of the estimated -$0.46 by -6.52%, while revenue for the quarter reached $174.00k , missing expectations by -68.93%.
Earnings released on 28 Feb 2022
EPS came in at -$0.43 falling short of the estimated -$0.42 by -2.38%, while revenue for the quarter reached $333.00k , missing expectations by -67.86%.
Earnings released on 9 Nov 2021
EPS came in at -$0.39 falling short of the estimated -$0.35 by -11.43%, while revenue for the quarter reached $153.00k , missing expectations by -76.09%.
Earnings released on 5 Aug 2021
EPS came in at -$0.34 surpassing the estimated -$0.40 by +15.00%, while revenue for the quarter reached $3.48m , beating expectations by +408.03%.
CLDX Stock Performance
Access detailed CLDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
